Alvotech and Teva get US FDA approval of Selarsdi

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva

Ami Organics accredited Gold Medal by EcoVadis

The Gold Medal distinction places the company in the top 5% of all organizations assessed within EcoVadis's rigorous framework globally

Suven Life Sciences to present phase-2 results on Samelisant at AAN 2024

Global Phase-3 study initiation expected in the second half of 2024

Laurus Labs forms JV company

KRKA holds 51% and Laurus Labs holds 49% shareholding

Croda and AAHI partner to drive innovation in vaccine development

The exclusive agreement between AAHI and Croda includes a collaborative effort in research and development

Teva confirms efficacy and safety of Ajovy for prevention of migraine

Ajovy confirms efficacy in new Phase 3 data significantly reducing the number of migraine days per month

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData

A significant proportion of healthcare professionals still tend to favor branded drugs

Dr. Reddy's launches drug-free migraine management device Nerivio in Europe

Ginkgo Bioworks and Novo Nordisk to collaborate across R&D value chain

The companies also plan to collaborate on several early pipeline projects, further technology exploration, and engineering of scalable manufacturing solutions across Novo Nordisk's portfolio